Siavash Ghorbani
Co-Founder at Stilla
21 Jan 2026Europes Newest Unicorn Joins, Eleven Labs Eyes $11B, Sequoia Looks To Anthropic, $1M X Article Payou
Stilla Launch Day: Demo Video + Siavash Ghorbani Interview
The hosts play Stilla's launch video showing the AI teammate working natively across Slack, GitHub, Linear and meetings, then interview co-founder Siavash Ghorbani live hours after the public launch. He explains "streaming context," how multiplayer usage spread organically among design partners including Ramp, Shopify, Legora, Lovable and Spotify, human-in-the-loop trust controls, why Stilla is horizontal by design but vertical in go-to-market, and the story of choosing General Catalyst despite higher competing term sheets.
Breaking: von der Leyen Announces EU Inc at Davos
The hosts react live to Ursula von der Leyen's Davos speech announcing the 28th regime and a "truly European company structure" called EU Inc, with 48-hour fully online company registration and a unified capital regime across member states, and favorite-and-retweet Andreas Klinger's post on the milestone. They then kill time before the next guest mocking an X article claiming financial independence comes from making your coffee at home.
Alexandros Pantalis Introduces Fagos
Fagos co-founder and CEO Alexandros Pantalis joins and introduces the company he founded five years ago with his co-founder Adele (CTO), stating the mission "to end bacterial disease." He frames bacterial disease as the second leading cause of death for humans and a top killer of animals; the interview continues beyond this part.
Phagos: Fighting Antibiotic Resistance with Bacteriophages
Phagos' co-founder frames antibiotic resistance — already 1 in 6 human infections resistant and growing 10-15% a year — as an existential threat that could end modern medicine within 15 years. Instead of antibiotics, the company uses bacteriophages, bacteria's natural predators, combined with AI and modern microbiology to match the right phage to each infection. He says they just raised a €25M Series A and are the first company authorized in Europe to sell personalized phage treatments as mainstream veterinary pharmaceuticals. Asked about competition, he notes roughly 150 phage players worldwide (about 20 in animal health) and says Phagos differs by building a personalized phage 'cocktail' per farm rather than a broad-spectrum fix that would repeat antibiotics' resistance mistakes.